1) COPD with pulmonary fibrosis
COPD继发肺间质纤维化
1.
The clinical characters of COPD with pulmonary fibrosis were detected by high-resolution computed tomography (HRCT), pulmonary function test (PFT) and so on.
本研究运用高分辨CT(HRCT)、肺功能等指标以观察COPD继发肺间质纤维化的临床特征。
2) Idiopathic Pulmonary Fibrosis
特发性肺间质纤维化
1.
Review on Recent Therapeutic Condition and Progress of Idiopathic Pulmonary Fibrosis;
特发性肺间质纤维化的治疗现状与进展
2.
Detection and significance of serum cytokines levels in patients with idiopathic pulmonary fibrosis;
特发性肺间质纤维化患者血清细胞因子的检测及其意义
3.
Treatment of idiopathic pulmonary fibrosis with Qihong Decoction;
芪红汤治疗特发性肺间质纤维化的临床研究
3) idiopathic pulmonary interstitial fibrosis
特发性肺间质纤维化
1.
Effects of sodium ferulate on oxidative stress and pulmonary function of idiopathic pulmonary interstitial fibrosis patients;
阿魏酸钠对特发性肺间质纤维化患者氧化应激及肺功能的影响
2.
Objective:To study the effect of rehmannia (RM) on expression of transforming growth factor β-receptor type I (TGF-βR I) in idiopathic pulmonary interstitial fibrosis (IPIF).
目的:研究生地干预对特发性肺间质纤维化中转化生长因子β受体Ⅰ(TGF-βRⅠ)表达的影响。
4) Idiopathic pulmonary fibrosis(IPF)
特发性肺间质纤维化(IPF)
5) pulmonary fibrosis
肺间质纤维化
1.
Effect of anti-fibrosis drug on the concentration of cefotaxim in bronchioalveolar lavage fluid in rats with Bleomycin-induced pulmonary fibrosis;
抗纤维化药物对肺间质纤维化大鼠支气管肺泡灌洗液中头孢噻肟浓度的影响
2.
Clinical analysis of 43 cases of chronic obstructive pulmonary disease with idiopathic pulmonary fibrosis;
慢性阻塞性肺疾病合并肺间质纤维化43例临床分析
3.
Effect and molecular mechanism of qidankeli in the treatment of pulmonary fibrosis;
芪丹颗粒治疗肺间质纤维化的实验研究
6) Pulmonary interstitial fibrosis
肺间质纤维化
1.
Effects of polysaccharide from Ecklonia kurome on pulmonary interstitial fibrosis induced by bleomycin in rats;
昆布多糖对博来霉素诱导的大鼠肺间质纤维化的影响
2.
Distribution and drug resistance analysis of infection pathogens of pulmonary interstitial fibrosis;
肺间质纤维化合并感染的病原菌分布及耐药性分析
3.
Study of clinical characteristics of chronic obstructive pulmonary disease with idiopathic pulmonary interstitial fibrosis;
慢性阻塞性肺疾病合并肺间质纤维化的临床研究
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条